Review Article

Pharmacological and Nonpharmacological Prevention of Atrial Fibrillation after Coronary Artery Bypass Surgery

Majid Haghjoo, MD, FESC, FACC*

Cardiac Electrophysiology Research Center, Rajaie Cardiovascular, Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Received 09 December 2011; Accepted 20 December 2011

Abstract

Atrial fibrillation (AF) is the most common complication of coronary artery bypass graft surgery (CABG). The reported incidence of AF after CABG varies from 20% to 40%. Postoperative AF (POAF) is associated with increased incidence of hemodynamic instability, thromboembolic events, longer hospital stays, and increased health care costs. A variety of pharmacological and nonpharmacological strategies have been employed to prevent AF after CABG. Preoperative and postoperative beta blockers are recommended in all cardiac surgery patients as the first-line medication to prevent POAF. Sotalol and amiodarone are also effective and can be regarded as appropriate alternatives in high-risk patients. Corticosteroids and biatrial pacing may be considered in selected CABG patients but are associated with risk. Magnesium supplementation should be considered in patients with hypomagnesemia. There are no definitive data to support the treatment with nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, procainamide, and propafenone, or anterior fat pad preservation to reduce POAF.

Keywords: Atrial fibrillation • Coronary artery bypass • Drug therapy • Cardiac pacing, artificial

Introduction

Postoperative atrial fibrillation (POAF) is a common complication of coronary artery bypass graft surgery (CABG), occurring in 20% to 40% of patients.1-4 POAF has been associated with increased incidence of acute thromboembolic events, longer hospital stays, and increased health care costs.5-7 POAF may also identify a subset of patients with increased in-hospital and long-term mortality.8-10 Therefore, prevention of POAF is of great importance.

A variety of pharmacological and nonpharmacological strategies have been used to prevent atrial fibrillation (AF) after CABG. Efficacy of beta blockers, amiodarone, sotalol, magnesium, and atrial pacing has been assessed in several randomized and nonrandomized clinical trials. This review tries to present an update on the preventive strategies of AF following CABG.

Pharmacological interventions

Beta blockers

Because patients recovering from cardiac surgery often
have enhanced sympathetic tone, the risk of postoperative AF is increased. Beta blockers antagonize the effects of catecholamines on the myocardium and are, thus, expected to prevent AF after cardiac surgery. Multiple randomized and nonrandomized clinical trials have evaluated the efficacy of the beta blocker in the prevention of POAF in patients undergoing CABG.11-36 Majority of these studies have shown a significant reduction in POAF by beta-blocker prophylaxis in cardiac surgery patients. In addition, three landmark meta-analyses have been conducted to confirm the efficacy of prophylactic beta blockers against post-CABG AF and demonstrated a reduced incidence of post-CABG AF (OR: 0.39, 95% CI: 0.28-0.52).2, 37, 38 Following these remarkable results, updated American Heart Association/American College of Cardiology (AHA/ACC) 2006/2011 and recent ESC 2010 guidelines recommended beta-blocker prophylaxis to prevent POAF in cardiac surgery patients in the absence of contraindications.39, 40 However, there are still questions not adequately addressed in these guidelines: first, the optimal beta blocker for PAOF prevention is not defined. Second, exact timing of beta-blocker initiation (preoperative vs. postoperative) in cardiac surgery patients for AF prevention is not clear.

**Optimal beta blocker for AF prevention after CABG**

Different kinds of beta blockers have been used in randomized clinical trials (RCT), including propranolol, atenolol, timolol, nadolol, betaxolol, acebutolol, landiolol, carvedilol, and bisoprolol. Propranolol was the most commonly used beta blocker in earlier clinical trials, and metoprolol was the most commonly used beta blocker in recent studies. There is no head-to-head comparison of propranolol and metoprolol. There are, however, a few recent trials that compared the efficacy of the different types of beta blockers in reducing POAF in patients undergoing surgical revascularization. Two RCTs and one nonrandomized study investigated the efficacy of carvedilol compared with metoprolol in preventing AF following CABG.41-43 A retrospective review of 110 patients who underwent CABG or valvular surgery demonstrated a significant reduction in POAF in the carvedilol group versus the metoprolol or atenolol group.42 Two RCTs clearly confirmed the superiority of carvedilol over metoprolol for AF prevention after CABG;41, 42 nonetheless, the number of patients in both of these studies was small. The higher efficacy of carvedilol may be explained by a more comprehensive sympatholytic action (beta-1, beta-2, and alpha-1 adrenergic receptor blockers) than that of the other beta blockers and its antioxidant and anti-inflammatory actions.44, 45

Efficacy of the beta blocker may be influenced by the route of administration in postoperative patients. Two studies specifically investigated the efficacy and safety of intravenous and oral beta blockers: in the pilot study by Balcecyte-Harris et al.,46 intravenous esmolol was compared with the oral beta blocker. This study was terminated prematurely because of significant adverse effect and lack of any reduction in POAF in the intravenous esmolol group. However, a second study, comparing oral and intravenous metoprolol, clearly showed the superiority of intravenous metoprolol with no serious adverse effects.47 Similarly, a trend toward more frequent adverse effects was reported in a trial using intravenous propranolol versus placebo.33 Considering the higher adverse effects and controversial superiority of the intravenous formulations of the available beta blockers, it appears that oral beta blockers are better tolerated and easier to use than intravenous counterparts.

**Preoperative vs. postoperative initiation of beta blockers**

Timing of beta-blocker prophylaxis may have an important effect on the development of POAF.48 Patients who received both pre- and postoperative propranolol were less likely to develop AF (5%) than those who received only preoperative (40%; p value < 0.001) or postoperative (27%; p value < 0.01) beta blockers.24 Similarly, Ali et al.14 showed that in patients in whom preoperative beta blockers (metoprolol, atenolol, sotalol, or propranolol) was continued after surgery experienced a lower rate of AF compared with patients in whom beta-blocker therapy was not continued after surgery (17% vs. 38%; p value < 0.02). Two recent meta-analyses have similarly shown a statistically significant difference in protection against post-CABG AF with regard to the timing of the prophylaxis.37, 49 These data indicated that beta blockers are more effective in reducing the incidence of POAF when given both before and after CABG.

**Amiodarone**

Efficacy and safety of both oral and intravenous amiodarone have been investigated in several studies.50-63 These studies demonstrated that prophylactic amiodarone not only reduced the occurrence of POAF (OR: 0.50, 95% CI: 0.42-0.59) and significantly shortened the hospital stay but also reduced the incidence of cerebrovascular accident and postoperative ventricular tachyarrhythmia; it, however, had no effect on postoperative mortality.39 Currently, preoperative administration of amiodarone is deemed class IIa indication for prophylactic therapy in patients at high risk for postoperative AF in the latest AHA/ACC and European Society of Cardiology (ESC) guidelines for AF management.39, 40

**Oral amiodarone**

The utility of oral amiodarone was described for the first time by Daoud et al.31 for POAF prevention. In that study, cardiac surgery patients were randomized to placebo or
one week administration of oral amiodarone and followed by postoperative amiodarone. Results of this study showed that oral amiodarone significantly reduced the incidence of postoperative AF compared with the placebo (23% vs. 43%: p value = 0.03). Efficacy and safety of the oral amiodarone were also tested in five randomized trials. The largest trial, the PAPABEAR study (Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valvular Repair, or Replacement) randomized 601 patients to either oral amiodarone or placebo.64 Oral amiodarone (10 mg/kg qd) or placebo was administered 6 days before surgery and continued 6 days after surgery. The incidence of AF was more significantly lower in the amiodarone group than in the placebo group (16% vs. 29.5%; p value < 0.001). This effect was consistently evident in patients < 65 years or ≥ 65 years, patients who received preoperative beta blocker, or those who did not receive beta blocker before surgery, and CABG only or valve surgery or both. However, the amiodarone-treated group experienced more side effects, which required drug discontinuation compared with the placebo group (11.4% vs. 5.3%; p value = 0.02).

**Intravenous amiodarone**

Early studies using intravenous amiodarone yielded conflicting results. The Amiodarone Reduction in Coronary Heart (ARCH) trial in 300 CABG patients demonstrated that the postoperative intravenous administration of amiodarone (1 g/d for 2 days) significantly reduced the incidence of POAF (47% vs. 35; p value = 0.01). Nevertheless, these results were not confirmed in other studies. In addition, the perioperative administration of intravenous amiodarone has been associated with bradycardia and hypotension. More recent studies using postoperative intravenous (2 days) followed by oral amiodarone (up to 30 days) have provided better results in terms of AF prevention and side effect profile.

Concomitant administration of beta blockers and amiodarone was reported in 20-80% of the patients. In the Budeus et al. study, the reasons for beta-blocker withdrawal did not differ between the placebo and the amiodarone groups (39% vs. 33%, p value = 0.53). Therefore, the concomitant administration of beta blockers and amiodarone for POAF prevention is not associated with a higher incidence of bradycardia and hypotension compared with amiodarone alone.

In summary, it would be logical to consider either oral amiodarone before and after cardiac surgery or a short course (48 hrs.) of intravenous amiodarone initiated after surgery and followed by oral therapy as an effective strategy to reduce the incidence of postoperative AF.

**Sotalol**

Sotalol is a class III antiarrhythmic agent with potent beta-blocking activity. As a result, it would be a suitable drug for POAF prevention after cardiac surgeries. Sotalol has been proven to be an effective agent across all the clinical trials using this drug. In a study on 255 CABG patients with and without valvular surgery, sotalol administration 2 hours before anesthesia induction resulted in a significant reduction in POAF by 43% compared with placebo. This agent is even more effective when started before surgery and maintained in the postoperative period. Gomes et al. demonstrated that oral sotalol prevented POAF by 67% when initiated 48 hours before surgery and continued for four days postoperatively.

Although sotalol is an effective drug for post-CABG AF, this drug has been associated with significant adverse effects, including bradycardia and hypotension especially in high doses. In the study of Suttrop and colleagues, high-dose sotalol (240 mg daily) was associated with a higher incidence of adverse drug events necessitating cessation of therapy than low-dose (120 mg daily) sotalol (10.7% vs. 2.9%; p value < 0.02). Gomes et al. similarly showed that sotalol with a daily dose of 160-240 mg significantly reduced POAF without appreciable side effects (5% significant bradycardia and no torsades de pointes). In another study, a high-dose sotalol regimen (320 mg daily) was associated with significant bradycardia in 22% of the patients. Although sotalol is an effective drug for post-CABG AF, this drug has been associated with significant adverse effects, including bradycardia and hypotension especially in high doses. In the study of Suttrop and colleagues, high-dose sotalol (240 mg daily) was associated with a higher incidence of adverse drug events necessitating cessation of therapy than low-dose (120 mg daily) sotalol (10.7% vs. 2.9%; p value < 0.02). Gomes et al. similarly showed that sotalol with a daily dose of 160-240 mg significantly reduced POAF without appreciable side effects (5% significant bradycardia and no torsades de pointes). In another study, a high-dose sotalol regimen (320 mg daily) was associated with significant bradycardia in 22% of the patients. However, significant adverse effects are still an important issue, not least in patients with electrolyte disturbance.

**Procainamide**

Two studies evaluated the efficacy and safety of prophylactic procainamide in preventing AF after CABG. In the first study, oral procainamide for 4 days after operation did not significantly reduce the incidence of POAF in patients who underwent CABG. In the study of Laub et al., the oral or intravenous administration of procainamide within 1 hr of the patient’s arrival in the intensive care unit and continued for 5 days marginally reduced the episodes of POAF after CABG compared with the placebo.

**Propafenone**

Effect of prophylactic propafenone was evaluated in two studies. Kowey et al. tested the efficacy and safety of two doses (675 mg or 450 mg daily) of oral propafenone in a group of 293 patients who underwent CABG. Oral propafenone 675 mg/day did not significantly reduce the incidence of AF and had no impact on the length of hospital stay.
second study similarly showed no benefit for propafenone administration in reducing POAF.\textsuperscript{76}

**Magnesium**

Hypomagnesemia has been suggested as a cause of both supraventricular and ventricular tachycardias, and it is an independent risk factor for the development of POAF in cardiac surgery patients. Therefore, it has been hypothesized that magnesium supplementation may reduce the incidence of POAF after heart surgery. Several clinical trials have examined the use of intravenous magnesium sulfate for the prevention of AF after CABG.\textsuperscript{77,78} Some studies reported a dramatic reduction in POAF in patients who received magnesium supplement,\textsuperscript{77,78} whereas other studies failed to show any benefit for intravenous magnesium administration.\textsuperscript{79,80} A meta-analysis of eight identified RCTs revealed that the use of intravenous magnesium supplementation was associated with a significant reduction in the AF incidence after CABG (OR: 0.64, 95% CI: 0.47-0.87; p value = 0.004).\textsuperscript{81} The additive effect of the intravenous magnesium to other antiarrhythmic agents has also been investigated in a few studies. In the study of Bert et al.,\textsuperscript{82} magnesium did not offer additional significant benefit to that provided by beta blockers. Solomon et al.\textsuperscript{83} randomized 167 CABG patients to receive propranolol alone or propranolol plus magnesium. Similarly, the results of this study failed to show any advantages for the propranolol-treated patients compared with the propranolol plus magnesium-treated patients (19.5% vs. 22.4%; p value = 0.65). Considering these data, the routine administration of magnesium supplement is not recommended in all patients undergoing surgical revascularization except for patients with hypomagnesemia.

**Anti-inflammatory agents**

POAF may be in part related to the systemic inflammatory response induced by extracorporeal circulation in on-pump cardiac surgery patients. Consequently, it is expected that anti-inflammatory agents, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDS) prevent AF after open heart operations.

In a randomized clinical trial on 90 CABG patients, the postoperative administration of NSAIDs (IV ketorolac for 24 hours followed by oral ibuprofen) significantly decreased the incidence of POAF compared to those receiving pain medications other than NSAIDs (4.3% vs. 25.5%, p value = 0.01).\textsuperscript{84} On the other hand, the NAFARM (Naproxen as Prophylaxis against Atrial Fibrillation after Coronary Artery Bypass Graft Surgery) randomized trial failed to show the effect of naproxen on the prevention of POAF after CABG.\textsuperscript{85} Additionally, there was a significant increase in acute renal failure in patients receiving naproxen 275 mg twice daily.

Halonen et al.\textsuperscript{86} investigated the role of corticosteroid therapy for the prevention of POAF after cardiac surgery. In this double-blind randomized study, 241 patients were randomized to receive either 100-mg hydrocortisone (the first dose in the evening of the operative day, followed by one dose every 8 hours during the next 3 days) or placebo. Incidence of POAF was significantly lower in the hydrocortisone group (30%) than in the placebo group (48%, p value = 0.004) without increasing superficial or deep wound infection or other major complications. Meta-analysis of corticosteroid therapy showed a 26-45% reduction in POAF and shorter hospital stay.\textsuperscript{87} However, due to potential detrimental effects on glucose metabolism, wound healing, and infection, their use for AF prevention is limited. In the recent ESC 2010 guidelines, corticosteroids are considered as a class IIB recommendation to reduce the incidence of AF after cardiac surgery.\textsuperscript{40}

**Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers**

It has been demonstrated that angiotensin II has an important role in the development of AF in nonsurgical patients. Accordingly, it has been hypothesized that antagonizing the effects of angiotensin II with drug therapy may help to prevent AF. However, the role of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) has never been investigated in a randomized clinical trial in post-CABG patients. In addition, there are safety issues about the potential risk of renal failure in patients receiving ACEIs and ARBs early after surgery.\textsuperscript{40}

**Statins**

Inflammation has been claimed to be involved in the pathogenesis of the AF after cardiac surgery. On the other hand, a potent anti-inflammatory action has been suggested for statins in cardiac surgery patients. Similar to the other anti-inflammatory agents, statins are expected to reduce the incidence of POAF after CABG. Interestingly, a meta-analysis of eight RCTs showed a significant benefit for the preoperative statin administration in reducing the incidence of AF (RR: 0.57, 95% CI: 0.45-0.72, p value < 0.0001) and total hospital stay (weighted mean difference 0.66 days, 95% CI: 0.3-1.01 days, p value = 0.0004) after cardiac surgery.\textsuperscript{88} In addition, there was an association between length of preoperative statin therapy and POAF risk reduction (3% reduction per day, p value = 0.008). However, there was no dose-response relationship between statins and POAF (p value = 0.47). It appears that preoperative statin prophylaxis is effective in preventing POAF after cardiac surgery and earlier treatment produces greater benefit. In the latest ESC guidelines for AF management, statins are considered for the prophylaxis of new-onset AF after isolated CABG, combined with valvular surgery.\textsuperscript{40}
Nonpharmacological interventions

Atrial pacing

Overdrive atrial pacing may exert its preventive effect on post-CABG AF by suppressing bradycardia-induced irregular heart rate, overdrive suppression of atrial premature beats, suppressing compensatory pauses after atrial premature beats, and resynchronizing atrial activation.98 Efficacy of right atrial (RA), left atrial (LA), and biatrial (BiA) pacing has been studied in several randomized studies. Fan et al.99 evaluated the efficacy of BiA pacing in preventing post-CABG AF compared with single site atrial pacing in 132 patients. BiA pacing (12.5%) was more effective than the other three groups (LA, 36.4%; RA, 33.3%; no pacing, 41.9%; p value < 0.05) in reducing the incidence of POAF. Hospital stay was also significantly decreased in the BiA pacing group. Similarly, Daoud et al.100 reported a lower rate of AF in patients treated by BiA pacing (10%) compared with those treated by RA pacing at 45 bpm (28%, p value = 0.03) and RA-triggered pacing at a rate of ≥ 85 bpm (32%, p value = 0.01). Still, there was no difference between the three groups in terms of the duration of hospital stay, morbidity, and mortality. These encouraging results with BiA pacing were not confirmed in the AFIST II (The Atrial Fibrillation Suppression Trial II), using atrial septal pacing40 and the Hakala study, using RA pacing.92 In a review of 10 RCTs, AF incidence was reduced by overdrive pacing regardless of the atrial pacing site or pacing protocol (fixed rate vs. flexible algorithm).93 It appears that BiA pacing is more effective than single-site pacing; be that as it may, available data do not permit a firm recommendation on the application of this intervention in a post-CABG setting. Recently, the ESC 2010 guidelines on AF management considered BiA pacing as a class IIB recommendation for AF prevention after cardiac surgery.40

Anterior fat pad excision (ventral cardiac denervation)

An anterior fat pad (AFP) is located on the anterior surface of the atria between the aorta and right pulmonary artery.94 Canine data suggest that AFP excision during cardiothoracic surgery would reduce the risk of developing POAF.95 96 Melo et al. confirmed these data in a prospective nonrandomized study.97 They showed a lower incidence of post-CABG AF in patients with AFP excision (7%) compared with a control group (27%). However, another human study on 55 patients undergoing CABG paradoxically showed that the preservation of the human AFP during CABG decreased the incidence of POAF.98 This paradoxical result was, similarly, repeated in an RCT on 220 patients undergoing CABG (21% vs. 10%, p value = 0.025).99 In a pilot study, 131 patients were randomized to on-pump CABG or off-pump CABG.100 The patients who had AFP removal (on-pump) had a significantly higher incidence of POAF (OR: 3.49, 95% CI: 1.09-11.18; p value = 0.035). Nonetheless, nonrandomized extension of this study (n = 320) failed to show any benefit for the preservation or excision of AFP in relation to post-CABG AF.101 Alex et al.102 evaluated the effectiveness of AFP excision in reducing the incidence of POAF in 140 CABG patients. They also failed to show any benefit for AFP excision (p value = 0.3). The AFIST-III (Atrial Fibrillation Suppression Trial-III), the largest and latest RCT to date, randomized 180 CABG patients to either AFP preservation or AFP excision.103 The result of this trial revealed no benefit for AFP maintenance in reducing the incidence of POAF. Taken together, available data indicated that there is no benefit for AFP preservation or removal in preventing post-CABG AF.

Conclusions

Beta blockers represent the most cost-effective prophylaxis for POAF in the setting of CABG. Preoperative and postoperative beta blockers are recommended in all cardiac surgery patients as the first-line medication to prevent POAF. Sotalol and amiodarone are also effective and can be considered appropriate alternatives in high-risk patients. Patients who need urgent CABG may benefit from a combination of intravenous and oral amiodarone in addition to beta blockers. Corticosteroids and BiA pacing may be considered in selected CABG patients but are associated with risk. Magnesium supplementation should be considered in patients with hypomagnesemia. There are currently no definitive data to support the notion that treatment with NSAIDS, ACEI, ARB, procainamide, and propafenone, or AFP retention could reduce POAF.

References

1. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg 1993;56:539-549.
2. Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supraventricular arrhythmias after coronary artery bypass surgery. A meta-analysis of randomized control trials. Circulation 1991;84:II236-244.
3. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-1073.
4. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT; Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-1729.
5. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, Tarazi R, Shroyer AL, Sethi GK, Grover FL, Hammermeister KE. Atrial fibrillation after cardiac surgery. A major morbid event? Ann Surg 1997;226:501-511.
Pharmacological and Nonpharmacological Prevention of Atrial Fibrillation ...

6. Hakala T, Pitkänen O, Hippeläinen M. Feasibility of predicting the risk of atrial fibrillation after coronary artery bypass surgery with logistic regression model. Scand J Surg 2002;91:339-344.

7. Lahtinen J, Biancari F, Salmela E, Morison M, Satta J, Rainio P, Rimpiäläinen J, Lepojärvi M, Juvonen T. Postoperative atrial fibrillation is a major cause of stroke after on-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77:1241-1244.

8. Villarreal RP, Hafarman R, Liu BC, Kar B, Lee VV, Eladya M, Lopez JA, Rasekh A, Wilson JM, Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004;43:742-748.

9. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after coronary artery surgery. N Engl J Med 1997;336:1429-1434.

10. Kalavrouziotis D, Buth KJ, Ali IS. The Impact of new-onset atrial fibrillation on in-hospital mortality following cardiac surgery. Chest 2007;131:833-839.

11. Babin-Ebell J, Keith PR, Elert O. Efficacy and safety of low-dose propranolol versus diltiazem in the prophylaxis of supraventricular tachyarrhythmia after coronary artery bypass grafting. Eur J Cardiothorac Surg 1996;10:412-416.

12. Gomes JA, Ip J, Santonio-Rugiu F, Mehta D, Ergin A, Lansman S, Pe E, Newhouse TT, Chao S. Oral d, l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999;34:334-339.

13. Abel RM, van Gelder HM, Pores IH, Liguori J, Gielchinsky I, Parsonnet V. Continued propranolol administration following coronary bypass surgery: antiarrhythmic effects. Arch Surg 1983;118:727-731.

14. Ali IM, Sanalla AA, Clark V. Beta-blocker effects on postoperative atrial fibrillation. Eur J Cardiothorac Surg 1997;11:1154-1157.

15. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O'Brien B, Carroll S, Crystal E, Thorpe KE, Gent M; Beta-Blocker Length Of Stay (BLOS) study. Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. Am Heart J 2003;145:226-232.

16. Daoud P, Corcos T, Gandjbakhch I, Levassure JP, Cabrol A, Cabrol C. Prevention of atrial fibrillation or flutter by acebutolol after coronary bypass grafting. J Thorac Cardiovasc Surg 1998;116:125-134.

17. Ivey MF, Ivey TD, Bailey WW, Williams DB, Hessel EA, 2nd, Miller DW, Jr. Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization: a randomized trial. J Thorac Cardiovasc Surg 1983;85:214-218.

18. Khuri SF, Okike ON, Josa M, Vander Salm TJ, Assoussia S, Leone L, Silverman A, Siouffi S, Olukotun AY. Efficacy of nadolol in preventing supraventricular tachycardia after coronary artery bypass grafting. Am J Cardiol 1987;60:51D-58D.

19. Lamb RK, Prabhakar G, Thorpe JA, Smith S, Norton R, Dyde JA. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur Heart J 1989;9:32-36.

20. Martinussen JH, Lokk A, Szczepanski C, Alstrup P. Supraventricular tachyarrhythmias after coronary bypass surgery: a double blind randomized trial of prophylactic low dose propranolol. Thorac Cardiovasc Surg 1988;36:206-207.

21. Matangi MF, Neutez JM, Graham KJ, Hill DG, Kerr AR, Barratt-Boyes BG. Arrhythmia prophylaxis after aorta-coronary bypass: the effect of minidose propranolol. J Thorac Cardiovasc Surg 1985;89:439-443.

22. Matangi MF, Strickland J, Garbe GJ, Habib N, Basu AK, Burgess JJ, Maitland A, Busse EF. Atenolol for the prevention of arrhythmias following coronary artery bypass grafting. Can J Cardiol 1989;5:229-234.

23. Materne P, Larbuisson R, Collignon P, Linet R, Kulbertus H. Prevention by beta-blockers of rhythm disorders following coronary bypass surgery. Int J Cardiol 1985;8:275-286.

24. Mohr S, Smolinsky A, Goor DA. Prevention of supraventricular tachyarrhythmia with low-dose propranolol after coronary bypass. J Thorac Cardiovasc Surg 1981;81:840-845.

25. Myhre ES, Sorlie D, Aarbakke J, Hals PA, Straume B. Effects of low dose propranolol after coronary bypass surgery. J Cardiovasc Surg (Torino) 1984;25:348-352.

26. Oka Y, Frishman W, Becker RM, Kadiash A, Stron J, Matsumoto M, Okrin L, Frater R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 10. Beta-adrenoceptor blockade and coronary artery surgery. Am Heart J 1980;99:255-269.

27. Ormerod OJ, McGregor CG, Stone DL, Wisbey C, Petch MC. Arrhythmias after coronary bypass surgery. Br Heart J 1984;51:618-621.

28. Paulil DL, Tidwell SL, Guyton SW, Harvey E, Woolf RA, Holmes JR, Anderson RP. Beta-blockade to prevent atrial dysrhythmias following coronary bypass surgery. Am J Surg 1979;173:419-421.

29. Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg 1987;94:331-335.

30. Salazar C, Frishman W, Friedman S, Patel J, Lin YT, Oka Y, Frater RW, Becker RM. Beta-blockade therapy for supraventricular tachyarrhythmias after coronary surgery: a propranolol withdrawal syndrome? Angiology 1979;30:816-819.

31. Silverman NA, Wright R, Levitsky S. Efficacy of low-dose propranolol in preventing postoperative supraventricular tachyarrhythmias: a prospective, randomized study. Ann Surg 1982;96:194-197.

32. Stephenson LW, MacVaugh H, 3rd, Tomaszello DN, Josephson ME. Propranolol for prevention of postoperative cardiac arrhythmias: a randomized study. Ann Thorac Surg 1980;29:113-116.

33. Veitch RJ, Nicolaides EP, Ilkoeuke JK, Liassides C, Cleary J, Cooper WB. Incidence and prevention of supraventricular tachyarrhythmias after coronary bypass surgery. Int J Cardiol 1986;13:125-134.

34. Wenke K, Parsa MH, Imhof M, Kemkes BM. Efficacy of metoprolol in prevention of supraventricular arrhythmias after coronary artery bypass grafting [in German]. Z Kardiol 1999;88:647-652.

35. White HD, Antman EM, Glyman MA, Collins JJ, Cohn LH, Shemin RJ, Friedman PL. Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. Circulation 1984;70:479-484.

36. Williams JB, Stephenson LW, Holford FD, Langer T, Dunkman WB, Josephson ME. Atrial fibrillation prophylaxis by propranolol after coronary artery surgery. Ann Thorac Surg 1982;34:435-438.

37. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002;106:75-80.

38. Zimmer J, Pezzullo J, Choucar W, Southard J, Kokkinos P, Karakis S, Greenberg MD, Singh SN. Meta-analysis of antiarrhythmic therapy in the prevention of postoperative atrial fibrillation and the effect on hospital length of stay, costs, cerebrovascular accidents, and mortality in patients undergoing cardiac surgery. Am J Cardiol 2003;91:1137-1140.

39. Fuster V, Ryden LE, Cannon DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prysowtowsky EN, Tamargo JL, Wann LS, Smith SC, Jr, Priori SG. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-367.

40. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhoff P, Lip GY, Schagen S, Savelieva I, Torp-Pedersen S, Al-Attar N, Building Research and Clinical Practice Guidelines. Cardiothoracic Surgery Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-367.
prospective, placebo-controlled study. Am Heart J 1991;121:355-358.

Hohnloser SH, Meinertz T, Dammbacher T, Steiert K, Jähnchen L, Halonen J, Hakala T, Auvinen T, Karjalainen J, Turpeinen A, Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf S, Reimert K, Feindt P, Gams E, Lehmann N, Wienen H, Sack S, Erbel R, Perings C. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blind, placebo-controlled, randomized study. Eur Heart J 2006;27:1584-1591.

Mitchell LB. Prophylactic Amiodarone for the Prevention of Atrial Fibrillation That Begin Early After Revascularization, Valvular Repair, or Replacement (PAPABEAR): preliminary results. American Heart Association Scientific Sessions; November 12, 2003; Orlando, FL. www.medscape.com/viewarticle/46467420 May 2011).

Yagdi T, Nalbantgil S, Ayik F, Apaydın A, Islamoğlu F, Posacioglu H, Calkavur T, Atay Y, Baker S. Amiodarone reduced the incidence of atrial fibrillation after coronary artery bypass grafting at a low dose-sotalol. A prospective, double-blind, randomized, placebo-controlled study. Ann Thorac Surg 2007;84:1113-1119.

Suttle M, Mandrioli D, Zanchetti A, Menozzi G. Oral amiodarone for prophylaxis of atrial fibrillation after cardiac surgery: a meta-analysis. Eur Heart J 1999;20:1133-1139.

Intravenous amiodarone for prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCHO) trial. J Am Coll Cardiol 1999;34:343-347.

Hohlocher SH, Meinertz T, Dammacher T, Stiebert K, Jähnchen E, Zehender M, Friedrich G, Just H. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J 1999;121:89-95.

Lee SH, Chang CM, Lu MJ, Lee RJ, Cheng JJ, Hung CR, Chen SA. Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2000;70:157-161.

Redle JD, Khurana S, Marzan R, McCullough PA, Stewart JR, Westveer DC, O'Neill WW, Bassett JS, Tepe NA, Frumin HI. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. Am Heart J 1999;138:144-150.

Treggiari-Venzi MM, Waebler JL, Pemeger TV, Suter PM, Adamec R, Romand JA. Intravenous amiodarone or magnesium sulphate is not cost-beneficial prophylaxis for atrial fibrillation after coronary artery bypass surgery. Br J Anaesth 2000;85:690-695.

Bagshaw SM, Galbraith PD, Mitchell LB, Sauve R, Exner DV, Ghi G. Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 2006;82:1927-1937.

Katarjki A, DeMarchena E, Boloooki H. Oral amiodarone reduces incidence of postoperative atrial fibrillation. Ann Thorac Surg 1999;68:1599-1603.

Maras D, Bokovski SD, Popovic Z, Neskovcevic N, Kovacevic S, Otsaevic P, Marinovich V, Vuk L, Borzanovic M, Nastasic S, Jovanovic T, Bojic M, Bojovic R, Popovic AD. Single-loading dose of oral amiodarone for the prevention of new-onset atrial fibrillation after coronary artery bypass surgery. Am Heart J 2001;141:E148.

Budeus M, Hennersdorf M, Perings S, Röhlen S, Schnitzerl S, Felix O, Rentert K, Feindt P, Gams E, Lehmann N, Wienen H, Sack S, Erbel R, Perings C. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blind, placebo-controlled, randomized study. Eur Heart J 2003;24:2252-2259.

Mitchell LB, DeMarchena E, Boloooki H. Oral amiodarone reduces incidence of postoperative atrial fibrillation. Ann Thorac Surg 1999;68:1599-1603.

Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2006;114:I1-4.

Butler J, Harriss DR, Sinclair M, Westaby S. Amiodarone prophylaxis for tachycardias after coronary artery surgery: a meta-analysis. Eur Heart J 2006;27:2846-2857.

Wagoner DR. C-reactive protein in patients with atrial arrhythmias: a prospective, double-blind, placebo-controlled, randomized study. Eur Heart J 2005;26:II200-206.

Pfitzner ME, Kloter-Weber UC, Huber M, Osswald S, Buser PT, Skarvan K, Stulz PM. Prevention of supraventricular tachyarrhythmias after open heart operation by low-dose sotalol: a prospective, double-blind, randomized, placebo-controlled study. Ann Thorac Surg 1997;64:1113-1119.

Sutter MJ, Kingma JH, Tjon Joe Gin RM, van Hemel NM, Koomen EM, Defauw JA, Adan AJ, Ernst SM. Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. J Thorac Cardiovasc Surg 1990;100:921-926.

Nyström U, Edvardsson N, Berggren H, Pizzarelli GP, Rådegån K. Oral sotalol reduces the incidence of atrial fibrillation after coronary artery bypass surgery. Thorac Cardiovasc Surg 1993;41:34-37.

Evrad P, Gonzalez M, Jamar J, Malhomme B, Blommaert D, Eucher P, Installé E. Prophylaxis of supraventricular and ventricular arrhythmias after coronary artery bypass grafting with low-dose sotalol. Ann Thorac Surg 2006;80:151-156.

Jocque L, Evenepoel M, Marenne F, Evrad P, Verhelst R, Dion R, Goenen M. Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1994;8:431-436.
Pharmacological and Nonpharmacological Prevention of Atrial Fibrillation...

71. Suttrop MJ, Kingma JH, Peels HO, Koomen EM, Tijssen JG, van Hemel NM, Defauw JA, Ernst SM. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991;68:1163-1169.

72. Weber UK, Oswald S, Buser P, Huber M, Skarvan K, Stulz P, Pfeifer M. Significance of supraventricular tachyarrhythmias after coronary artery bypass graft surgery and their prevention by low-dose sotalol: a prospective double-blind randomized placebo-controlled study. J Cardiovasc Pharmacol Ther 1998;3:209-216.

73. Gold MR, O’Gara PT, Buckley MJ, DeSanctis RW. Efficacy and safety of propranolol in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol 1996;78:975-979.

74. Laub GW, Janeira L, Muralidharan S, Riemb J, Chen C, Neary M, Fernandez J, Adkins MS, McGrath LB. Prophylactic propranolol for prevention of atrial fibrillation after coronary artery bypass grafting: a prospective, double-blind, randomized, placebo-controlled pilot study. Crit Care Med 1993;21:1474-1478.

75. Kowey PR, Yannicelli D, Amsterdam E; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 2004;94:663-665.

76. Merrick AF, Odom NJ, Keenan DJ, Grotte GJ. Comparison of propranolol to atenolol for the prophylaxis of postcardiostomy supraventricular tachyarrhythmias: a prospective trial. Eur J Cardiothorac Surg 1995;9:146-149.

77. Fanning WJ, Thomas CS, Jr, Roach A, Tomichek R, Alford WC, Stoney WS, Jr. Prophylaxis of atrial fibrillation with magnesium sulfate after coronary artery bypass grafting. Ann Thorac Surg 1991;52:529-533.

78. Nurozler F, Tokgozoglu L, Pasaoglu I, Boke E, Ersoy U, Bozer AY. Atrial fibrillation after coronary artery bypass surgery: predictors and the role of MgSO4 replacement. J Card Surg 1996;11:421-427.

79. Parikka H, Toivonen L, Pellinen T, Verkkala K, Jarvinen A, Niimenen MS. The influence of intravenous magnesium sulphate on the occurrence of atrial fibrillation after coronary artery by-pass operation. Eur Heart J 1993;14:251-258.

80. Kaplan M, Kut MS, Icer UA, Demirtas MM. Intravenous magnesium sulfate prophylaxis for atrial fibrillation after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:344-352.

81. Alghamdi AA, Al-Radi OO, Latter DA. Intravenous magnesium for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and meta-analysis. J Card Surg 2005;20:293-299.

82. Bert AA, Reinert SE, Singh AK. A beta-blocker, not magnesium, is effective prophylaxis for atrial tachyarrhythmias after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2001;15:204-209.

83. Solomon AJ, Berger AK, Trivedi KK, Hannan RL, Katz NM. The combination of propranolol and magnesium does not prevent postoperative atrial fibrillation. Ann Thorac Surg 2000;69:126-129.

84. Cheruku KK, Ghani A, Ahmad F, Pappas P, Silverman PR, Zelingier A, Silver MA. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol 2004;7:13-18.

85. Horbach SJ, Lopes RD, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirena C, de Paola AA; NAFFARM Investigators. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFFARM randomized trial. Am J Med 2011;124:1036-1042.

86. Halonen J, Halonen P, Järvinen O, Taskinen P, Auvinen T, Tarkka M, Hippiäinen M, Juvonen T, Hartikainen J, Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 2007;297:1562-1567.

87. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose–response meta-analysis. Circulation 2009;119:1853-1866.

88. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration-and dose-response meta-analysis. J Thorac Cardiovasc Surg 2010;140:364-372.

89. Fan K, Lee K, Lau CP. Mechanisms of atrial pacing for prevention of postoperative atrial fibrillation - Insights from a clinical trial. Card Electrophysiol Rev 2003;7:147-153.

90. Fan K, Lee KL, Chia CS, Lee JW, He GW, Cheung D, Sun MP, Lau CP. Effects of atrial pacing in prevention of postoperative atrial fibrillation after coronary artery bypass surgery. Circulation 2000;102:755-760.

91. Daoud EG, Dabir R, Archambeau M, Morady F, Strickberger SA. Randomized double-blind trial of simultaneous right and left atrial epicardial pacing for prevention of post-open heart surgery atrial fibrillation. Circulation 2000;102:761-765.

92. Hakala T, Valhola AJ, Turpeinen AK, Hedman AE, Vuorenniemi RE, Kajralainen JM, Vajanto IS, Kouri J, Jaakkola PA, Hartikainen JE. Right atrial overdrive pacing does not prevent atrial fibrillation after coronary artery bypass surgery. Europace 2005;7:170-174.

93. Archbold RA, Schilling RJ. Atrial pacing for the prevention of atrial fibrillation after coronary artery bypass graft surgery: a review of the literature. Heart 2004;90:129-133.

94. Chioo CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad. Circulation 1997;95:2573-2584.

95. Carlson MD, Gheas AS, Hsu J, Martin PJ, Levy MN, Jacobs G, Waldo AL. Selective stimulation of parasympathetic nerve fibers to the human sinoatrial node. Circulation 1992;85:1311-1317.

96. Zhuang S, Zhang Y, Mowrey KA, Li J, Tabata T, Wallick DW, Popovic ZB, Grimm RA, Natalie A, Mazgalev TN. Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation 2002;106:1853-1858.

97. Melo J, Voigt P, Sonmez B, Ferreira M, Abecassis M, Rebocho M, Timoteo A, Aguier C, Tansal S, Arabati H, Dion R. Ventral cardiac denervation reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004;127:511-516.

98. Cummings JE, Gill I, Akhrass R, Dery MA, Biblo LA, Quan KJ. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol 2004;43:994-1000.

99. Omran AS, Karimi A, Ahmadi H, Yazdanifard P, Sheikh Fahollahi M, Tazik M. Prophylactic ventral cardiac denervation: does it reduce incidence of atrial fibrillation after coronary artery bypass grafting? J Thorac Cardiovasc Surg 2010;140:1036-1039.

100. Davis Z, Jacobs HK, Bonilla J, Anderson RR, Thomas C, Forst W. Retaining the aortic fat pad during cardiac surgery decreases postoperative atrial fibrillation. Heart Surg Forum 2000;3:108-112.

101. Davis Z, Jacobs HK. Aortic fat pad destruction and post operative atrial fibrillation. Card Electrophysiol Rev 2003;7:185-188.

102. Alex J, Guvendik L. Evaluation of ventral cardiac denervation as a prophylaxis against atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2005;79:517-520.

103. White CM, Sander S, Coleman CI, Gallagher R, Takata H, Humphrey C, Henyan N, Gillespie EL, Kluger J. Impact of epicardial anterior fat pad retention on postcardiotoracic surgery atrial fibrillation incidence: the AFIST-III Study. J Am Coll Cardiol 2007;49:298-303.